ARWR
Price
$21.66
Change
-$0.67 (-3.00%)
Updated
Aug 29, 04:35 PM (EDT)
Capitalization
3.09B
94 days until earnings call
IFRX
Price
$1.60
Change
+$0.43 (+36.75%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
67.75M
62 days until earnings call
Interact to see
Advertisement

ARWR vs IFRX

Header iconARWR vs IFRX Comparison
Open Charts ARWR vs IFRXBanner chart's image
Arrowhead Pharmaceuticals
Price$21.66
Change-$0.67 (-3.00%)
Volume$1.25K
Capitalization3.09B
InflaRx
Price$1.60
Change+$0.43 (+36.75%)
Volume$18.5K
Capitalization67.75M
ARWR vs IFRX Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. IFRX commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a StrongBuy and IFRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (ARWR: $22.34 vs. IFRX: $1.17)
Brand notoriety: ARWR: Notable vs. IFRX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 114% vs. IFRX: 549%
Market capitalization -- ARWR: $3.09B vs. IFRX: $67.75M
ARWR [@Biotechnology] is valued at $3.09B. IFRX’s [@Biotechnology] market capitalization is $67.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 0 FA rating(s) are green whileIFRX’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 0 green, 5 red.
  • IFRX’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than IFRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 7 TA indicator(s) are bullish while IFRX’s TA Score has 5 bullish TA indicator(s).

  • ARWR’s TA Score: 7 bullish, 4 bearish.
  • IFRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than IFRX.

Price Growth

ARWR (@Biotechnology) experienced а +7.66% price change this week, while IFRX (@Biotechnology) price change was +30.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.74%. For the same industry, the average monthly price growth was +15.52%, and the average quarterly price growth was +29.97%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

IFRX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-0.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($3.09B) has a higher market cap than IFRX($67.7M). ARWR YTD gains are higher at: 18.830 vs. IFRX (-52.632). IFRX has higher annual earnings (EBITDA): -44.6M vs. ARWR (-52.51M). ARWR has more cash in the bank: 900M vs. IFRX (48M). IFRX has less debt than ARWR: IFRX (599K) vs ARWR (353M). ARWR has higher revenues than IFRX: ARWR (573M) vs IFRX (163K).
ARWRIFRXARWR / IFRX
Capitalization3.09B67.7M4,563%
EBITDA-52.51M-44.6M118%
Gain YTD18.830-52.632-36%
P/E RatioN/AN/A-
Revenue573M163K351,534%
Total Cash900M48M1,875%
Total Debt353M599K58,932%
FUNDAMENTALS RATINGS
ARWR vs IFRX: Fundamental Ratings
ARWR
IFRX
OUTLOOK RATING
1..100
2114
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4057
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IFRX's Valuation (64) in the Biotechnology industry is in the same range as ARWR (94). This means that IFRX’s stock grew similarly to ARWR’s over the last 12 months.

IFRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that IFRX’s stock grew similarly to ARWR’s over the last 12 months.

IFRX's SMR Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that IFRX’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (40) in the Biotechnology industry is in the same range as IFRX (57). This means that ARWR’s stock grew similarly to IFRX’s over the last 12 months.

ARWR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IFRX (100). This means that ARWR’s stock grew similarly to IFRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRIFRX
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
83%
Bearish Trend 19 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DOMOX10.780.05
+0.47%
Domini Impact International Equity Instl
DRLAX8.95N/A
N/A
BNY Mellon Developed Markets RE Scs - A
RCLIX44.77N/A
N/A
T. Rowe Price US Large-Cap Core I
CSPYX21.84N/A
N/A
Columbia Small Cap Index Inst3
TBLRX12.63N/A
N/A
Transamerica Balanced II R